Loading...
XNASFENC
Market cap170mUSD
Dec 23, Last price  
6.21USD
1D
3.67%
1Q
25.71%
Jan 2017
190.19%
Name

Fennec Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:FENC chart
P/E
—
P/S
8.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.92%
Rev. gr., 5y
%
Revenues
21m
+1,284.50%
0000000000000000170,00001,535,00021,252,000
Net income
-16m
L-35.40%
0-19,245,000-19,103,000-13,357,000-13,600,000-3,012,000-7,823,0004,685,000-5,163,0001,845,000-2,176,000-659,000-2,789,000-7,046,000-9,888,000-12,460,000-17,922,000-17,456,000-24,839,000-16,045,000
CFO
-17m
L-5.07%
0-12,261,000-13,475,000-13,303,000-10,808,000-4,688,000-1,928,000-3,226,000-2,994,000-2,210,000-1,699,000-1,862,000-2,124,000-3,641,000-7,826,000-9,060,000-15,595,000-14,222,000-18,058,000-17,143,000

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
URL
https://fennecpharma.com/
IPO date
Jun 05, 2001
Employees
36
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
21,252
1,284.50%
1,535
 
Cost of revenue
34,023
24,124
17,223
Unusual Expense (Income)
NOPBT
(12,771)
(22,589)
(17,223)
NOPBT Margin
Operating Taxes
1,125
110
Tax Rate
NOPAT
(12,771)
(23,714)
(17,333)
Net income
(16,045)
-35.40%
(24,839)
42.29%
(17,456)
-2.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,669
529
BB yield
-0.56%
-0.21%
Debt
Debt current
21
Long-term debt
30,956
24,899
4,988
Deferred revenue
Other long-term liabilities
(4,988)
Net debt
17,708
1,125
(16,112)
Cash flow
Cash from operating activities
(17,143)
(18,058)
(14,222)
CAPEX
Cash from investing activities
Cash from financing activities
6,638
20,732
4,978
FCF
(18,828)
(23,714)
(17,333)
Balance
Cash
13,269
23,774
21,100
Long term investments
Excess cash
12,206
23,697
21,100
Stockholders' equity
(73,695)
(59,366)
(37,442)
Invested Capital
93,027
81,696
58,202
ROIC
ROCE
EV
Common stock shares outstanding
26,574
26,275
26,006
Price
11.22
16.88%
9.60
118.18%
4.40
-40.94%
Market cap
298,160
18.20%
252,240
120.44%
114,426
-35.20%
EV
315,868
253,365
98,314
EBITDA
(12,771)
(22,457)
(17,209)
EV/EBITDA
Interest
3,394
978
126
Interest/NOPBT